A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
The Effects of Teriparatide on Bone Microarchitecture as Determined by High Resolution Magnetic Resonance Imaging and Digital Topological Analysis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3X8
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85704
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Colorado
-
Lakewood, Colorado, United States, 80227
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Nebraska
-
Omaha, Nebraska, United States, 68131
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- postmenopausal (after the "change of life") women with osteoporosis
- between the ages of 45-85
- have low bone mass as determined by a bone density test
- have at least one prior atraumatic vertebral or nonvertebral fracture(with a T-score of -2.0 or lower at the lumbar spine, total hip, or femoral neck) or, no prior fracture (with a T-score of -3.0 or lower at these same sites)
- could have taken up to 5 years total of certain oral osteoporosis medications such as alendronate, risedronate, or ibandronate
Exclusion Criteria:
- have conditions that would affect the bone in the region of the wrist or have had a previous fracture of either wrist which might affect results of study
- have a metal implant or have had a hip replacement in either hip which might affect results of study
- have an increased risk of osteosarcoma; includes Paget's disease of bone, a previous bone tumor, or x-ray treatment to the skeleton
- currently have active or suspected diseases that affect the bone, other than osteoporosis
- have abnormal levels of calcium, parathyroid hormone in blood, or other laboratory values
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Teriparatide
20 micrograms (mcg) teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
|
20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Change From Baseline in Surface-to-Curve Ratio (SCR) in the Distal Radius at Month 18 Endpoint
Time Frame: Baseline, 18 months
|
SCR is a measure of the computed ratio of plate-like to rod-like structures in a given volume of trabecular bone and reflects the integrity of the trabecular network.
The higher the value for SCR, the more intact the trabecular network.
Least squares (LS) mean of the percent change from baseline to 18 months is from a mixed model repeated measurements analysis.
The model included terms for investigator site, prior bisphosphonate use, visit and baseline.
|
Baseline, 18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Change From Baseline in Surface-to-Curve Ratio (SCR) in the Distal Radius at Month 24 Endpoint
Time Frame: Baseline, 24 months
|
SCR is a measure of the computed ratio of plate-like to rod-like structures in a given volume of trabecular bone and reflects the integrity of the trabecular network.
The higher the value for SCR, the more intact the trabecular network.
Least squares (LS) mean of the percent change from baseline to 24 months is from a mixed model repeated measurements analysis.
The model included terms for investigator site, prior bisphosphonate use, visit and baseline.
|
Baseline, 24 months
|
|
Percent Change From Baseline in Cortical Thickness (CT) in the Distal Radius at Month 18 and 24 Endpoint
Time Frame: Baseline, 18, 24 months
|
Cortical thickness (CT) is the thickness of both cortices in a given volume of bone.
Least squares (LS) mean of the percent change from baseline to 18, 24 months is from a mixed model repeated measurements analysis.
The model included terms for investigator site, prior bisphosphonate use, visit and baseline.
|
Baseline, 18, 24 months
|
|
Percent Change From Baseline in Topological Erosion Index (TEI) in the Distal Radius at Month 18 and 24 Endpoint
Time Frame: Baseline, 18, 24 months
|
TEI is the ratio of the sum of topological parameters expected to increase with bone erosion compared to the sum of those expected to decrease.
The lower the value for TEI, the more intact the trabecular network.
Least squares (LS) mean of the percent change from baseline to 18, 24 months is from a mixed model repeated measurements analysis.
The model included terms for investigator site, prior bisphosphonate use, visit and baseline.
|
Baseline, 18, 24 months
|
|
Percent Change From Baseline in Bone Volume (BV)/Total Volume (TV) Ratio in the Distal Radius at Month 18 and 24 Endpoint
Time Frame: Baseline, 18, 24 months
|
BV/TV is the estimate of the ratio of detectable bone relative to the total volume of the region of interest.
Least squares (LS) mean of the percent change from baseline to 18, 24 months is from a mixed model repeated measurements analysis.
The model included terms for investigator site, prior bisphosphonate use, visit and baseline.
|
Baseline, 18, 24 months
|
|
Percent Change From Baseline in Surface-to-Curve Ratio (SCR) at Month 3, 6, 12, 18 and 24 Endpoint
Time Frame: Baseline, 3, 6, 12, 18, 24 months
|
SCR is a measure of the computed ratio of plate-like to rod-like structures in a given volume of trabecular bone and reflects the integrity of the trabecular network.
The higher the value for SCR, the more intact the trabecular network.
Least squares (LS) mean of the percent change from baseline to 3, 6, 12, 18, 24 months is from a mixed model repeated measurements analysis.
The model included terms for investigator site, prior bisphosphonate use, visit and baseline.
|
Baseline, 3, 6, 12, 18, 24 months
|
|
Percent Change From Baseline in Volumetric Bone Mineral Density (BMD) of Lumbar Spine at Month 18 Endpoint
Time Frame: Baseline, 18 months
|
Volumetric BMD is a measure of the amount of mineral in a given volume of bone, expressed as milligram per cubic centimeter (mg/cm³).
Least squares (LS) mean of the percent change from baseline to 18 months is from an analysis of variance (ANOVA).
The model included terms for investigator site and prior bisphosphonate use.
|
Baseline, 18 months
|
|
Percent Change From Baseline in Volumetric Bone Mineral Density (BMD) of Hip at Month 18 Endpoint
Time Frame: Baseline, 18 months
|
Volumetric BMD is a measure of the amount of mineral in a given volume of bone.
Least squares (LS) mean of the percent change from baseline to 18 months is from an analysis of variance (ANOVA).
The model included terms for investigator site and prior bisphosphonate use.
|
Baseline, 18 months
|
|
Percent Change From Baseline in the Estimate of Bone Strength of Lumbar Spine at Month 18 Endpoint
Time Frame: Baseline, 18 months
|
Finite Element Analysis of computed tomography (CT) data from spine is used to estimate the strength of a vertebral body using a virtual axial load.
Least squares (LS) mean of the percent change from baseline to 18 months is from an analysis of variance (ANOVA).
The model included terms for investigator site and prior bisphosphonate use.
|
Baseline, 18 months
|
|
Percent Change From Baseline in the Estimate of Bone Strength of Hip at Month 18 Endpoint
Time Frame: Baseline, 18 months
|
Finite Element Analysis of computed tomography (CT) data from hip is used to estimate the strength of the proximal femur with a virtual sideways fall.
Least squares (LS) mean of the percent change from baseline to 18 months is from an analysis of variance (ANOVA).
The model included terms for investigator site and prior bisphosphonate use.
|
Baseline, 18 months
|
|
Percent Change From Baseline in Areal BMD at the Lumbar Spine at Month 18 and 24 Endpoint
Time Frame: Baseline, 18, 24 months
|
Areal BMD is a measure of the amount of mineral in a given area of bone.
Least squares (LS) mean of the percent change from baseline to 18 and 24 months is from an analysis of variance (ANOVA).
The model included terms for investigator site and prior bisphosphonate use.
|
Baseline, 18, 24 months
|
|
Percent Change From Baseline in Areal BMD at the Femoral Neck at Month 18 and 24 Endpoint
Time Frame: Baseline, 18, 24 months
|
Areal BMD is a measure of the amount of mineral in a given area of bone.
Least squares (LS) mean of the percent change from baseline to 18 and 24 months is from an analysis of variance (ANOVA).
The model included terms for investigator site and prior bisphosphonate use.
|
Baseline, 18, 24 months
|
|
Percent Change From Baseline in Areal BMD Responses at Total Hip at Month 18 and 24 Endpoint
Time Frame: Baseline, 18, 24 months
|
Areal BMD is a measure of the amount of mineral in a given area of bone.
Least squares (LS) mean of the percent change from baseline to 18 and 24 months is from an analysis of variance (ANOVA).
The model included terms for investigator site and prior bisphosphonate use.
|
Baseline, 18, 24 months
|
|
Percent Change From Baseline in Areal BMD at ⅓ Distal Radius at Month 18 and 24 Endpoint
Time Frame: Baseline, 18, 24 months
|
Areal BMD is a measure of the amount of mineral in a given area of bone.
Least squares (LS) mean of the percent change from baseline to 18 and 24 months is from an analysis of variance (ANOVA).
The model included terms for investigator site and prior bisphosphonate use.
|
Baseline, 18, 24 months
|
|
Percent Change From Baseline in Areal BMD at Ultra-Distal Radius at Month 18 and 24 Endpoint
Time Frame: Baseline, 18, 24 months
|
Areal BMD is a measure of the amount of mineral in a given area of bone.
Least squares (LS) mean of the percent change from baseline to 18 and 24 months is from an analysis of variance (ANOVA).
The model included terms for investigator site and prior bisphosphonate use.
|
Baseline, 18, 24 months
|
|
Percent Change From Baseline in Serum Procollagen Type I N-Terminal Propeptide (PINP) at Month 3, 6 and 24 Endpoint
Time Frame: Baseline, 3, 6, 24 months
|
PINP is a measure of bone formation.
Least squares (LS) mean of the percent change from baseline to 3, 6, 24 months is from a mixed model repeated measurements analysis.
The model included terms for investigator site, prior bisphosphonate use, visit and baseline.
|
Baseline, 3, 6, 24 months
|
|
Percent Change From Baseline in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX) at Month 3, 6 and 24 Endpoint
Time Frame: Baseline, 3, 6, 24 months
|
CTX is a measure of bone resorption.
Least squares (LS) mean of the percent change from baseline to 3, 6, 24 months is from a mixed model repeated measurements analysis.
The model included terms for investigator site, prior bisphosphonate use, visit and baseline.
|
Baseline, 3, 6, 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 11996
- B3D-US-GHDJ (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.